Circulating CD14
biomarkers, tumor
immunity
immunotherapy
macrophages
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
02
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
21
8
2021
Statut:
ppublish
Résumé
Besides the interest of an early detection of ovarian cancer, there is an urgent need for new predictive and prognostic biomarkers of tumor development and cancer treatment. In healthy patients, circulating blood monocytes are typically subdivided into classical (85%), intermediate (5%) and non-classical (10%) populations. Although these circulating monocyte subsets have been suggested as biomarkers in several diseases, few studies have investigate their potential as a predictive signature for tumor immune status,tumor growth and treatment adaptation. In this study, we used a homogeneous cohort of 28 chemotherapy-naïve patients with ovarian cancer to evaluate monocyte subsets as biomarkers of the ascites immunological status. We evaluated the correlations between circulating monocyte subsets and immune cells and tumor burden in peritoneal ascites. Moreover, to validate the use of circulating monocyte subsets tofollow tumor progression and treatment response, we characterized blood monocytes from ovarian cancer patients included in a phase 1 clinical trial at baseline and following murlentamab treatment. We demonstrate here a robust expansion of the intermediate blood monocytes (IBMs) in ovarian cancer patients. We establish a significant positive correlation between IBM percentage and tumor-associate macrophages with a CCR2 This study, which links IBM level with immunosuppression and tumor burden in peritoneum, identifies IBMs as apotential predictive signature of ascites immune status and as a biomarker ofovarian cancer development and treatment response. EudraCT: 2015-004252-22 NCT02978755.
Sections du résumé
BACKGROUND
Besides the interest of an early detection of ovarian cancer, there is an urgent need for new predictive and prognostic biomarkers of tumor development and cancer treatment. In healthy patients, circulating blood monocytes are typically subdivided into classical (85%), intermediate (5%) and non-classical (10%) populations. Although these circulating monocyte subsets have been suggested as biomarkers in several diseases, few studies have investigate their potential as a predictive signature for tumor immune status,tumor growth and treatment adaptation.
METHODS
In this study, we used a homogeneous cohort of 28 chemotherapy-naïve patients with ovarian cancer to evaluate monocyte subsets as biomarkers of the ascites immunological status. We evaluated the correlations between circulating monocyte subsets and immune cells and tumor burden in peritoneal ascites. Moreover, to validate the use of circulating monocyte subsets tofollow tumor progression and treatment response, we characterized blood monocytes from ovarian cancer patients included in a phase 1 clinical trial at baseline and following murlentamab treatment.
RESULTS
We demonstrate here a robust expansion of the intermediate blood monocytes (IBMs) in ovarian cancer patients. We establish a significant positive correlation between IBM percentage and tumor-associate macrophages with a CCR2
CONCLUSIONS
This study, which links IBM level with immunosuppression and tumor burden in peritoneum, identifies IBMs as apotential predictive signature of ascites immune status and as a biomarker ofovarian cancer development and treatment response.
TRIAL REGISTRATION NUMBER
EudraCT: 2015-004252-22 NCT02978755.
Identifiants
pubmed: 32503947
pii: jitc-2019-000472
doi: 10.1136/jitc-2019-000472
pmc: PMC7279676
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Lipopolysaccharide Receptors
0
Receptors, IgG
0
Banques de données
ClinicalTrials.gov
['NCT02978755']
EudraCT
['2015-004252-22']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Climacteric. 2018 Feb;21(1):60-68
pubmed: 29231068
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
J Clin Invest. 2017 Aug 1;127(8):3039-3051
pubmed: 28691930
Pathol Int. 2009 May;59(5):300-5
pubmed: 19432671
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Oncol Rep. 2015 Sep;34(3):1269-78
pubmed: 26135617
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Acta Medica (Hradec Kralove). 2009;52(2):57-61
pubmed: 19777868
Trends Immunol. 2007 Dec;28(12):519-24
pubmed: 17981504
Mol Cancer Ther. 2017 Feb;16(2):312-322
pubmed: 27980102
Clin Exp Immunol. 2010 Sep;161(3):471-9
pubmed: 20636398
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
Oncotarget. 2017 Oct 7;8(59):99950-99965
pubmed: 29245952
Blood. 2011 Sep 22;118(12):e50-61
pubmed: 21803849
Clin Cancer Res. 1997 Jun;3(6):999-1007
pubmed: 9815777
Sci Rep. 2018 Dec 14;8(1):17862
pubmed: 30552344
Anticancer Res. 2009 Aug;29(8):2875-84
pubmed: 19661290
Lab Invest. 2011 Nov;91(11):1605-14
pubmed: 21808236
Immun Inflamm Dis. 2015 Jun;3(2):94-102
pubmed: 26029369
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Biochem Biophys Res Commun. 2004 Sep 17;322(2):637-43
pubmed: 15325277
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Sci Rep. 2015 Sep 11;5:13886
pubmed: 26358827
PLoS One. 2012;7(6):e38541
pubmed: 22685580
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Blood. 2007 Dec 15;110(13):4319-30
pubmed: 17848619
Eur J Surg Oncol. 2003 Feb;29(1):69-73
pubmed: 12559080
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Gynecol Oncol. 2014 Feb;132(2):490-5
pubmed: 24316306
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
Clin Exp Immunol. 2011 Apr;164(1):57-65
pubmed: 21361908
J Immunol. 2003 Jul 15;171(2):669-77
pubmed: 12847232
Gynecol Oncol. 2008 Jan;108(1):141-8
pubmed: 17988723
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
Oncoimmunology. 2018 Mar 15;7(5):e1424672
pubmed: 29721385